Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare Holdings's gross profit for the
six
months ended in Dec. 2025 was $429 Mil. Aspen Pharmacare Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was $1,056 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aspen Pharmacare Holdings had a gross margin of 43.64% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Aspen Pharmacare Holdings Gross Profit Related Terms
Aspen Pharmacare Holdings Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's Gross Profit distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,056 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aspen Pharmacare Holdings (APNHY) has a Gross Profit of $1,056 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Aspen Pharmacare Holdings and its competitors.
Is Aspen Pharmacare Holdings' Gross Profit too high?
Aspen Pharmacare Holdings' current Gross Profit is $1,056 Mil. Overall, Aspen Pharmacare Holdings has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' Gross Profit compare to ZTS and UTHR?
Aspen Pharmacare Holdings' Gross Profit of $1,056 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Aspen Pharmacare Holdings and its competitors. Aspen Pharmacare Holdings's current Gross Profit is $1,056 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (APNHY) is currently considered Fairly Valued. The stock's GF Value™ is $10.18, compared to a current price of $9.72 — trading 4.5% below its estimated fair value. The current Gross Profit is $1,056 Mil. Aspen Pharmacare Holdings' overall GF Score™ is 70/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Aspen Pharmacare Holdings (APNHY), the current Gross Profit is $1,056 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (APNHY) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of $9.72 is trading 4.5% below its estimated GF Value™ of $10.18.
GuruFocus considers Aspen Pharmacare Holdings to be Fairly Valued.
Key valuation signals for APNHY:
Gross Profit: $1,056 Mil
GF Value™: $10.18 vs. price of $9.72 (4.5% below fair value)
No single metric tells the full story. See the APNHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
70GF Score
Get the complete analysis for APNHY
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APNHY has been successfully added to your 
